Our platform represents a fundamentally new approach to immunotherapy. Our therapies have the potential to offer a cure for patients with the most difficult to treat hematologic conditions.
Tom Home Page
Recent Posts
- Cimeio Therapeutics Announces Poster Presentations at ASH 2023
- Cimeio Therapeutics Announces Research Collaboration With the University of Pennsylvania
- Cimeio Therapeutics Announces Publication of Seminal Epitope Editing Work in the Journal of Experimental Medicine
- Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
- Molecular Shielding of the Pan-Hematopoietic Marker CD45 May Enable a Targeted Universal Approach for Replacement of the Hematopoietic System
Recent Comments
No comments to show.